JOURNAL OF NEPHROLOGY肾脏病学杂志
JOURNAL OF NEPHROLOGY(英文缩写 J NEPHROL),ISSN 1121-8428,eISSN 1724-6059,中文译名:肾脏病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.406 | Q2 |
| 2022 | 3.400 | Q2 |
| 2023 | 2.700 | Q2 |
| 2024 | 2.600 | Q2 |
| 2025 | 2.600 | Q2 |
JOURNAL OF NEPHROLOGY 最新收录文献
-
1. Kidney health for all: caring for people, protecting the planet.
PMID:日期:2026-09-19The current kidney care model-focused on late-stage disease and in-center hemodialysis-is unsustainable because of costs, environmental burden, poor outcomes, and reduced quality of life. The 78th World Health Assembly's recognition of kidney disease as a serious health threat presents a critical opportunity to reshape kidney care. Aligned with this, the 2026 World Kidney Day theme, "Kidney Health for All: Caring for People, Protecting the Planet", calls for a systematic change. A sustainable model must prioritize early detection and prevention, reducing the need for kidney replacement therapy. Transplantation and home dialysis benefit people with kidney failure, the environment, and society. Dialysis itself must become more eco-friendly without compromising care quality, recognizing that planetary perturbations in turn affect kidney health. Conservative care should also be considered, particularly for elderly and frail patients, if the quality-of-life benefits outweigh the advantages offered by dialysis. Achieving this shift requires coordinated action across all stakeholders; education and engagement of the public, policy makers and health professionals to raise awareness about the threat of kidney disease; and an urgent move toward patient-centered care.
-
2. Validation of the kidney patient-reported experience measure in Spanish and Catalan.
PMID:日期:2026-09-19In recent years, interest in assessing the patient experience with healthcare has grown, given that it is a meaningful outcome of patient interactions with health services. The UK Kidney Association (UKKA) and Kidney Care UK commissioned the development of the Kidney Patient Reported Experience Measure (PREM). The aim of this study was to test the validity and reliability of the Kidney PREM in Spanish and Catalan. The Kidney PREM questionnaire was completed by 575 patients with chronic kidney disease (CKD). The mean (standard deviation [SD]) age was 66.3 (±14.3) years and 68.3 (±15), respectively, for each language. The measure's internal consistency for the global score was high for both the Spanish [Cronbach's alpha = 0.93] and Catalan [Cronbach's alpha = 0.94] versions. According to response distribution, most items had median scores of 7, on a 1-7 point scale, ie the maximum score. Exceptions were items in Transport, Needling, and Parking, with interquartile ranges (IQR) of 2-7; 2-6 and 2-7, respectively. Known-group validity was confirmed across all Kidney PREM dimensions according to groups defined by overall satisfaction (P < .001). The chi-square statistic was 931.041 and the associated p-value was less than 0.001, indicating a statistically significant difference between the observed and expected covariance matrices. Overall, the fit statistics and the goodness-of-fit indices were close to acceptable values, with comparative fit index and Tucker-Lewis Index of 0.90. Most of the loadings obtained a loading greater than 0.7, suggesting a good fit with their assigned dimensions in the original questionnaire. The Spanish version of the Kidney PREM may facilitate its wider use and support the evaluation and improvement of patient-centered care across diverse healthcare contexts.
-
3. Infiltrative Nephropathy in Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma: A Systematic Review and Attribution Analysis.
PMID:日期:2026-09-19Renal infiltration by chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is frequently identified histologically but is an uncommonly recognised cause of clinically significant kidney injury. As CLL/SLL cells may be incidental or coexist with other renal pathology, biopsy alone does not establish causality. We performed a PROSPERO-registered systematic review of MEDLINE and Embase (January 1990 to March 2026). Adults with native-kidney biopsy-confirmed CLL/SLL infiltration and extractable clinical or outcome data were included. Data were synthesised descriptively, and an exploratory clinicopathological attribution analysis evaluated infiltration burden and pattern alongside competing renal lesions. Thirty studies comprising 54 extracted data rows were included. Acute kidney injury occurred in 40/49 (81.6%), and dialysis was required at presentation in 17/47 (36.2%). Concurrent glomerular pathology was present in 19/54 (35.2%). Stronger attribution features were identified in 19/54 cases (35.2%), whereas alternative dominant renal lesions were present in 18/54 (33.3%). End-stage kidney disease (ESKD) was more frequent in the stronger-attribution group (7/18, 38.9%) than with an alternative dominant lesion (1/12, 8.3%). Renal recovery followed CLL/SLL-directed therapy in 34/47 (72.3%). Attribution of kidney dysfunction to CLL/SLL infiltration requires integrated clinicopathological assessment. Diffuse or extensive infiltration without competing renal pathology provides the strongest evidence for causality and carries a higher risk of ESKD, while renal recovery after CLL/SLL-directed therapy suggests AKI may be reversible in selected patients. Dialysis dependence at presentation was the clearest predictor of ESKD. All findings derive from case reports and small series and are of very low certainty (GRADE).
-
4. Graft Renal Vein Pulsatility as a Marker of Systemic Venous Congestion in Kidney Transplant Recipients: Concordance with the VExUS Score and Implications for Hemodynamic Management.
PMID:日期:2026-09-19Bedside volume assessment after kidney transplantation is unreliable, and whether pulsatility of the graft renal vein in the denervated, encapsulated allograft reflects systemic venous congestion was unknown. We tested its association with the Venous Excess Ultrasound Score (VExUS). Prospective study of adult kidney transplant recipients assessed on days 1,7 and months 1,3. Pulsatility was categorised from continuous to discontinuous or reversed flow (≥30% threshold) and tested against VExUS-defined congestion by Fisher exact test, with exact confidence intervals and Cohen kappa; secondary analyses addressed bioimpedance (BIA), examination, delayed graft function and tacrolimus. Eighty-eight recipients were transplanted, 80 completing follow-up; denominators were 86, 85, 82 and 80. Pulsatility was associated with VExUS on days 1 and 7 and month 1 (all p<0.05), not month 3. On day 1, the ≥30% threshold gave specificity 88% (95% CI 78-95) and low sensitivity 42% (20-67) for VExUS ≥1; at >50%, 94% (85-98) and 26% (9-51). Chance-corrected agreement was the highest of any method pair (kappa 0.32, day 1). Discontinuous or reversed flow occurred in only three recipients on day 1, too few to estimate. Pulsatility was unrelated to BIA and tacrolimus. Graft renal vein pulsatility was associated with systemic venous congestion, supporting the transplanted vein as a functional equivalent of the native one. Retrograde pressure transmission into a rigid capsule is a plausible but unproven mechanism. Abnormal pulsatility rules congestion in but, because sensitivity is low, does not rule it out; interventional studies are needed before it guides management.
-
5. Impact of recombinant human growth hormone treatment in children with growth disorders secondary to nephrotic syndrome.
PMID:日期:2026-09-15Patients with nephrotic syndrome (NS) treated with glucocorticoids often suffer from growth disorders. This study aimed to explore the impact of recombinant human growth hormone treatment in children with growth disorders secondary to NS. This retrospective study enrolled patients with NS treated at Guangzhou Women and Children's Medical Center between May 2015 and November 2023. Patients were divided into the recombinant human growth hormone group and the conventional group. The primary outcome was height increment. Secondary outcomes included height standard deviation score, predicted adult height standard deviation score, and height velocity. Among 129 enrolled children (89 in the recombinant human growth hormone group, 40 in the conventional group), the recombinant human growth hormone group showed significantly greater height increments at 6 months (4.80 ± 1.42 vs. 2.02 ± 0.91 cm), 12 months (9.07 ± 2.46 vs. 4.39 ± 1.73 cm), and 24 months (15.34 ± 5.20 vs. 7.88 ± 3.43 cm; all P < .001). Similarly, height standard deviation score and predicted adult height standard deviation score improvements were significantly greater in the recombinant human growth hormone group at all time points (all P < .001). Height velocity was also higher in the recombinant human growth hormone group at 6 and 12 months (both P < .001). These associations remained significant after multivariate adjustment. No significant differences in glucocorticoid exposure during follow-up were observed between groups. Multivariate analysis at 12 months indicated that cumulative glucocorticoid dosage was negatively associated with height standard deviation score (β=-.0022, 95% CI: -0.0041, -0.0004; P = .020) and predicted adult height (β=-.0148, 95% CI: -0.0288, -0.0008; P = .038). The results suggested that recombinant human growth hormone treatment in children with NS significantly improved height, height standard deviation score, predicted adult height standard deviation score, and height velocities, compared with conventional treatment.
-
6. Atypical hemolytic uremic syndrome in kidney transplantation.
6. 肾移植中的非典型溶血性尿毒症综合征PMID:日期:2026-09-15Atypical hemolytic uremic syndrome (aHUS) is a rare disorder that affects individuals of any age. It is caused by genetic abnormalities of the alternative complement pathway, arising from inherited or de novo mutations, or from acquired factors such as autoantibodies against complement proteins, including complement factor H. Clinically, aHUS is characterized by the classic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. However, its clinical presentation may be difficult to distinguish from typical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. aHUS is driven by uncontrolled activation of the alternative complement pathway, leading to endothelial injury and microvascular thrombosis. Atypical HUS may also occur after kidney transplantation, either as recurrence of the native disease or as de novo post-transplant thrombotic microangiopathy. The diagnosis of post-transplant aHUS relies on the presence of the above-mentioned classic triad and the exclusion of secondary causes such as thrombotic thrombocytopenic purpura and Shiga toxin-associated HUS. The pathophysiology is similar, involving either genetic mutations affecting complement proteins or acquired dysregulation due to autoantibodies. Historically, plasma exchange was used to replace dysfunctional complement regulators and remove circulating autoantibodies, with variable success. After transplantation, the disorder may either recur or develop de novo. In the past, plasmapheresis was considered beneficial. More recently, the availability of eculizumab, an anti-C5 monoclonal antibody that inhibits terminal complement activation, has become the treatment of choice, either as monotherapy or with plasma exchange. However, uncertainties remain regarding the optimal duration and dosing of long-term therapy, particularly in transplant recipients.
-
7. Glow-food illuminating nutritional value and enhancing taste in chronic kidney disease: a Mediterranean perspective.
PMID:日期:2026-09-15Chronic kidney disease (CKD) is a major public health concern and has recently been rated as a priority by the World Health Organization (WHO). Among the modifiable environmental risk factors, diet plays a pivotal role in the development and progression of CKD and its risk factors. Evidence consistently supports the protective role of Mediterranean- and plant-based diets in preventing CKD and reducing associated cardiovascular risks, in contrast to the adverse effects of Western dietary patterns. To ensure long-term dietary adherence in patients with CKD, nutritional strategies must be evidence-based, physiologically appropriate, sensorially satisfying, and culturally rooted. In this context, we introduce the concept of "glow-food," which emphasizes the use of seasonal, minimally processed Mediterranean ingredients in health-promoting dishes that are visually appealing and flavorful. This approach aims to bridge the gap between clinical dietary recommendations and patient experiences, highlighting that tailored nutrition can be both sustainable and enjoyable, thereby preserving the value of Mediterranean food heritage.
-
8. Serum N-terminal pro-B-type natriuretic peptide and physical performance in middle-aged and older patients with chronic kidney disease.
PMID:日期:2026-09-15Observational studies have reported that impaired physical performance is associated with an elevated risk for cardiovascular disease (CVD) in patients with non-dialysis chronic kidney disease (CKD). However, there is limited evidence supporting this finding from a pathological perspective. As such, the present study aimed to determine the association between physical performance variables and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, a biomarker for estimating CVD risk, in patients with non-dialysis CKD. This cross-sectional study involved 113 middle-aged and older patients with CKD (mean [ ± SD] age, 66 ± 9 years; 50.4% women). We evaluated serum NT-proBNP levels, handgrip strength, knee extension strength, 30-second chair stand test, maximal gait speed, 60-second single-leg stance test, and sit-and-reach tests. Decreased handgrip strength, knee extension strength, and 60-second single-leg stance score were associated with elevated serum NT-proBNP levels after adjusting for age, sex, hypertension, diabetes, dyslipidemia, body mass index, urinary albumin-to-creatinine ratio, estimated glomerular filtration rate, medication use (ie, diuretic use, β-blocker use, renin-angiotensin system inhibitor use), and physical activity level (all P < .05). Moreover, stepwise regression analysis revealed that the score for completion of the 60-second single-leg stance test was selected as a covariate of serum NT-proBNP levels, even after adjusting for muscle strength variable. Results of this study suggest that attenuated muscle strength and balance function tend to be associated with higher serum NT-proBNP levels in patients with non-dialysis CKD, which expands previous observational findings.
-
9. Unexpected finding of AA amyloidosis with novel genetic variants in the MEFV gene in patients undergoing kidney biopsy for proteinuria. A case series.
PMID:日期:2026-09-15Amyloidosis is a systemic clinical condition characterised by the extracellular deposition of misfolded proteins in various organs, most frequently involving the heart, kidneys, gastrointestinal tract, and bone marrow. Among its types, AA amyloidosis accounts for approximately 15% of cases and is mainly secondary to chronic infectious or inflammatory conditions. The association between Familial Mediterranean Fever (FMF) and AA amyloidosis is well-established, with the MEFV gene's M694V mutation being the most recognised risk factor. However, the role of other genetic variants often remains underestimated. This case series presents a spectrum of AA amyloidosis patients harbouring various MEFV gene variants. By emphasizing the clinical presentations and diagnostic challenges encountered, this report aims to highlight the clinical significance of heterozygous and less common variants that are frequently overlooked in the progression to AA amyloidosis.
-
10. Nephrology review frequency, associated factors, and outcomes among people with chronic kidney disease G5: a population-based cohort study in England.
10. 英国慢性肾脏病G5期患者肾脏病复查频率、相关因素及结局：一项基于人群的队列研究PMID:日期:2026-09-10Nephrologists support decision-making and preparation for kidney replacement therapy (KRT) and conservative kidney management (CKM). However, the frequency of nephrology review among people with chronic kidney disease (CKD) G5 has not been well characterised at the population level. We identified adults in England who reached CKDG5 between 2013-2018 using Clinical Practice Research Datalink Aurum, a primary care database covering 16.1% of the UK population, linked to Hospital Episode Statistics. Review frequency was defined as the annualised number of 90-day quarters with ≥1 nephrology-coded outpatient attendance or inpatient admission during the 720 days before and after index. We examined factors associated with review frequency and estimated adjusted outcome probabilities. Among 4,781 patients (44.2% female; median age, 74 years), 872 (18.2%) died without KRT and 2,614 (54.7%) initiated KRT, including 795 (16.6%) inpatient dialysis initiations. Lower review frequency was associated with older age, female sex, greater deprivation, dementia, and cerebrovascular disease, whereas Asian and Black ethnicity were associated with higher frequency than White ethnicity. Lower review frequency was associated with less KRT initiation and higher proportions of death without KRT and inpatient dialysis initiation. We provide a population-based description of the heterogeneity in nephrology contact and subsequent treatment pathways among people reaching CKDG5 by age, sex, deprivation, frailty, comorbidity, and ethnicity. These observational data highlight the need to better understand equity in access to nephrology care and the diverse care needs of people with CKDG5 beyond preparation for KRT.